ESR1 and breast cancer: Consistent with this idea, others have shown that oncogenic mutations that amplify cell growth sensitize cells to palbociclib treatment,73 and hyperactivation of mTOR (which also amplifies cell growth) sensitizes estrogen receptor positive breast cancer cells to Cdk4/6 inhibition in terms of permanent cell-cycle withdrawal.74